Clinical Trial Update: A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMN 351 in participants with Duchenne Muscular Dyst…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• BMN 351

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Duchenne Muscular Dystrophy | Phase 1, Phase 2 | Status: RECRUITING